American Academy of Family Physicians

Printer-friendly version

Share this on AAFP Connection

Share this page

FDA Warns Physicians Against Prescribing Fentora for Off-label Uses

By News Staff

The FDA has issued an alert for health care professionals warning them about the use of fentanyl buccal (i.e., Fentora) tablets after recent reports of deaths and other adverse events. The FDA says the deaths were the result of improper patient selection, dosing or product substitution.

Fentora is a potent opioid pain medication that should be used only for the treatment of breakthrough pain in cancer patients who are receiving opioid treatment and who have become tolerant. Of particular interest to family physicians, the FDA warns against using Fentora for any short-term pain, such as headaches or migraines, sports injuries, or postoperative pain.

Patients who take narcotic pain medications regularly become tolerant and are more resistant to the adverse effects of these medications than patients who take narcotic pain medication less frequently. For this reason, it is critical that Fentora not be used in patients who are not opioid tolerant, according to the FDA.

The alert also points out that Fentora is not a generic version of Actiq, which is an opioid that also contains fentanyl. Because Fentora is not a generic drug, it should not be prescribed as a substitute for Actiq or any other fentanyl-containing product. Fentora delivers more fentanyl to the blood than Actiq and other drugs that contain fentanyl, so using the same dose of Fentora can result in a fatal overdose.

The FDA has asked Cephalon Inc., the manufacturer of Fentora, to strengthen warnings and improve dosing instructions on the drug's product labeling. The FDA also has asked the company to improve its education plan for prescribers and pharmacists on the proper patient selection, dosing instructions and restrictions on substituting Fentora for other products.

Share this on AAFP Connection

Health of the Public

Study: PPI Does Not Routinely Improve Asthma Control

Recalled Oral Contraceptives Pose Pregnancy Risk

CDC to Fund 2D Vaccine Barcoding Pilot

2012 Immunization Schedules Reflect Multiple Changes

Study: Cognitive Decline Detected in Middle-aged Adults

CDC Toolkit Can Help Clinicians Fight Norovirus Infection

Patient-Centered Care Linked to Lower Mortality

Study: Inappropriate Cancer Screenings Continue

Novartis Manufacturing Plant Closes After Drug Mix-ups

FDA Announces Classwide REMS for TIRF Medications

New Infants' Acetaminophen Products Hit Store Shelves

Avoid Environmental Factors Linked to Breast Cancer

Risk for Thrombosis Prompts REMS for Rivaroxaban

Common Drugs Implicated in Most Emergency Hospitalizations

CDC Launches Campaign for Child Medication Safety

HHS Blocks Expanded OTC Access to Plan B

Push Is On to Vaccinate Pregnant, Postpartum Women

FDA Committee Votes to Broaden PCV13 Indication

AAFP Foundation Program Aims to Fight Chronic Disease

NIAAA Alcohol Screening Guide Targets Teens

Walgreens, AAFP Launch Flu Vaccine Pilot in Five States

Helping Patients Quit Smoking Starts With a Question

Trilipix Efficacy in Question, Says FDA

USPSTF Addresses Skin Cancer, Obesity, Cervical Cancer Screening

AAFP Endorses ACP Guideline on ED

ACIP Recommends Expanded HPV, Hepatitis B Vaccination

Bacterial Contamination Spurs Nasal Spray Recall

CDC Renews Call for PCV13 Vaccination

USPSTF Recommends Against PSA Screening

AAFP Supports HHS' Million Hearts Initiative

FDA Phases Out Primatene Mist Inhalers

AHRQ Guides Explain Benefits, Risks of GERD Treatments

Tar Wars Winner Gives Back

Office Champions Project Nets Smoking Cessation Gains

Multiple Lots of Oral Contraceptives Recalled

New Vaccine Review Finds Few Adverse Events

HPV Vaccination Rates Still Lag, Says CDC

Renal Injury Prompts Reclast Label Changes

High-dose Citalopram Linked to Abnormal Heart Rhythms

AHRQ Sleep Apnea Guides Review Diagnosis, Management

Board Chair Spotlights Breadth of Family Medicine Training

USPSTF Softens Stance on Bladder Cancer Screening

HHS Expands Coverage for Women's Preventive Services

Birth Defects Linked to Fluconazole Prompt FDA Warning

FDA Warns of Mixing Certain MAOIs, Serotonergic Drugs

Oseltamivir Concentration Revised to Ensure Accurate Dosing

Teledermatology Project Aids Underserved Patients

New Chantix Warnings Cite Cardiovascular Risk

Pertussis Outbreaks Lead to CDC Alert on PCR Testing